Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction
Laurens A. van Kleef, Sven Francque, Jhon Edison Prieto Ortíz, et al.
Gastroenterology (2024) Vol. 167, Iss. 2, pp. 357-367.e9
Open Access | Times Cited: 19

Showing 19 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 254
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 51
Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 24
Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2024
Majken T. Wingo, Carl A Andersen, Nadir M Bhuiyan, et al.
The American Journal of Medicine (2025)
Closed Access
The role of the advanced lung cancer inflammation index (ALI) in the risk of liver fibrosis and mortality among US adult MAFLD patients: a cross-sectional study of NHANES 1999–2018
Chunchun Yu, L. Chen, Wanting Hu, et al.
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access
A turning point in hepatology? EASL reflects on the first approved drug for MASH
Sven Francque, Aleksander Krag, Debbie L. Shawcross, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 2, pp. 192-194
Open Access | Times Cited: 4
Diagnostic accuracy of the LiverRisk score to detect increased liver stiffness among a US general population and subgroups
Laurens A. van Kleef, Jesse Pustjens, Harry L.A. Janssen, et al.
Journal of Clinical and Experimental Hepatology (2025) Vol. 15, Iss. 4, pp. 102512-102512
Open Access
The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologies
Renee Hernandez, Natasha S. Garcia-Rodriguez, Marco A. Arriaga, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Impact of Cardiometabolic Risk Factors on Hepatic Fibrosis and Clinical Outcomes in MASLD: A Population-based Multi-Cohort Study
Huiyul Park, Terry Cheuk‐Fung Yip, Eileen L. Yoon, et al.
JHEP Reports (2025), pp. 101388-101388
Open Access
Prediction of major liver-related events in the population using prognostic models
Fredrik Åberg, Ville Männistö
Gastroenterology report (2025) Vol. 13
Open Access
New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?
Marzia Tagliaferro, Mariapaola Marino, Valerio Basile, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 8, pp. 798-798
Open Access | Times Cited: 3
Accurate non-invasive detection of MASH with fibrosis F2-F3 using a lightweight machine learning model with minimal clinical and metabolomic variables
Konstantinos Stefanakis, Geltrude Mingrone, Jacob George, et al.
Metabolism (2024) Vol. 163, pp. 156082-156082
Closed Access | Times Cited: 2
Baseline and dynamic MAF-5 score to predict liver fibrosis and liver-related events in general population with MASLD
Shanghao Liu, Xuanwei Jiang, Junliang Fu, et al.
Clinical Gastroenterology and Hepatology (2024)
Closed Access | Times Cited: 1
Comments on “Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction”
Yuting Guan, Jiaming Yang, Zudong Xu
Gastroenterology (2024)
Closed Access | Times Cited: 1
Combined impact of prediabetes and hepatic steatosis on cardiometabolic outcomes in young adults
Wonsuk Choi, Minae Park, Sojeong Park, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Reply to Guan et al
Laurens A. van Kleef, Willem Pieter Brouwer
Gastroenterology (2024)
Closed Access
Monitoring the liver as a part of the cardio-renal-metabolic continuum – What is cooking and burning with non-invasive tests and treatment options?
Špela Volčanšek, Andrej Janež, Manfredi Rizzo, et al.
Journal of Diabetes and its Complications (2024), pp. 108875-108875
Closed Access
Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease
Joana D’Arc Matos França de Abreu, Rossana Santiago de Sousa Azulay, Vandílson Pinheiro Rodrigues, et al.
Biomedicines (2024) Vol. 12, Iss. 11, pp. 2542-2542
Open Access
The fibrosis investigating navigator in diabetes (FIND): A tool to predict liver fibrosis risk in subjects with diabetes
Mingkai Li, Hongsheng Yu, Sizhe Wan, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access
Page 1

Scroll to top